drugset
drugset / Trial / NCT03161054

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

NCT03161054 ↗

Phase 2 Completed 21 enrolled Fondazione Italiana Linfomi - ETS
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study of metronomic chemotherapy in elderly non-fit patients (\>65 years) with aggressive B-Cell lymphomas

Timeline

Start
2017-09-12
Primary completion
2020-04-22
Completion
2021-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg Oral
Subject Etoposide Small molecule 50 mg Oral
Subject Prednisone Other / unclassified 25 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vinorelbine Small molecule 30 mg Oral

Indications

aggressive B-cell non-Hodgkin lymphoma